{
    "id": 27591,
    "fullName": "ROS1 V2089M",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ROS1 V2089M lies within the protein kinase domain of the Ros1 protein (UniProt.org). V2089M has been identified in the scientific literature (PMID: 26372962), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6098,
        "geneSymbol": "ROS1",
        "terms": [
            "ROS1",
            "c-ros-1",
            "MCF3",
            "ROS"
        ]
    },
    "variant": "V2089M",
    "createDate": "03/21/2018",
    "updateDate": "02/29/2020",
    "referenceTranscriptCoordinates": {
        "id": 102508,
        "transcript": "NM_002944",
        "gDna": "chr6:g.117310250C>T",
        "cDna": "c.6265G>A",
        "protein": "p.V2089M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13459,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13461,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13460,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13457,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13462,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13458,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13342,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 demonstrated decreased response to Alunbrig (brigatinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13346,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 were resistant to Xalkori (crizotinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13345,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 were resistant to Foretinib (GSK1363089) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 demonstrated decreased response to Cometriq (Cabometyx, cabozantinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13343,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 demonstrated decreased response to Zykadia (ceritinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13347,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29081,
            "profileName": "ROS1 V2089M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29093,
            "profileName": "CD74 - ROS1 ROS1 V2089M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29094,
            "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102508,
            "transcript": "NM_002944",
            "gDna": "chr6:g.117310250C>T",
            "cDna": "c.6265G>A",
            "protein": "p.V2089M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}